Sanger Sequencing and Next-Generation Sequencing Compared

Currently, the two most popular methods of DNA sequencing are Sanger sequencing and next generation sequencing (NGS). Whilst NGS has largely overtaken Sanger sequencing, it is still used by researchers today due to its simplicity and ease of use.

Credit: ktsdesign/Shutterstock

Sanger sequencing was developed in the 1970s by Frederick Sanger and was the original DNA sequencing method.

In Sanger sequencing, chain-terminating  nucleoside bases are incorporated into the DNA replication reaction. This results in a series of DNA chains truncated at each base pair in the sequence. The sequence is then read by separating these chains on a polyacrylamide gel.

Next generation is a newer method that can be used to sequence much larger pieces of DNA, or even whole genomes. It is based on sequencing during the DNA synthesis reaction. The reaction is carried out on a fixed surface. Each time a base is added, the new sequence information is read. Thousands of reactions can be sequenced simultaneously.

Illumina

The dominant next-generation sequencing platform is Illumina. It was originally developed by the company Solexa based on an array technology, bridge amplification, from Pascal Meyer and others, before being improved upon by Solexa scientists. This technology was acquired by Illumina in 2007.

Illumina’s method has a similar concept to Sanger sequencing. In Sanger sequencing, chain-terminating di-deoxynucleosidetriphosphates (ddNTPs) are incorporated into DNA chains during DNA replication using template DNA and a primer to begin the reaction.

In Illumina sequencing, reversible terminators are attached to regular deoxynucleosidetriphosphates (dNTPs). The terminator blocks extension of the DNA chain.

However, the terminators are reversible, so after readout, the terminator is removed and another base is added to the chain. The cycle is then repeated for the full read length of the fragment.

Detection

In Sanger sequencing, the terminated chains are separated on a polyacrylamide gel. The primers (dNTPs) are labeled with a radioactive isotope, or, more commonly, a fluorescent label. The sequence is then read out all at once. With fluorescence detection, four different fluorescent colors are used to distinguish the different bases.

For Illumina sequencing, detection is carried out using a fluorescent label bonded the dNTP. A single fluorescent dye is used for all bases, and each dNTP is added separately to distinguish them from one another.

DNA sequence yield

The primary practical difference between Sanger sequencing and next generation sequencing is the yield of sequence data.

Illumina’s sequencing machine can produce up to 20 mega bases (Mb) per hour with a read length of 100 bases from both ends of the template. Slab gel Sanger sequencing produces 0.0672 Mb/hr with a read length of 700 bp.

Cost

The relative cost of Sanger sequencing is higher than NGS. Sanger sequencing is estimated at about $500 per 1000 bases, compared to less than $0.50 per 1000 bases for NGS, according to a 2011 study.

When to use Sanger sequencing

Next generation sequencing technology is now preferred for certain jobs. Those include:

  • sequencing more than 100 genes simultaneously
  • expanding the number of targets to find novel variants
  • samples with low input amounts of starting material
  • microbial genomes for pathogen subtyping in critical outbreak situations

Sanger sequencing is still a good choice when:

  • sequencing single genes
  • Sequencing amplicon targets up to 100 base pairs
  • sequencing 96 samples or less
  • identifying of microbes
  • analyzing fragments
  • analyzing short tandem repeats (STRs)

Further Reading

Last Updated: Feb 26, 2019

Dr. Catherine Shaffer

Written by

Dr. Catherine Shaffer

Catherine Shaffer is a freelance science and health writer from Michigan. She has written for a wide variety of trade and consumer publications on life sciences topics, particularly in the area of drug discovery and development. She holds a Ph.D. in Biological Chemistry and began her career as a laboratory researcher before transitioning to science writing. She also writes and publishes fiction, and in her free time enjoys yoga, biking, and taking care of her pets.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Shaffer, Catherine. (2019, February 26). Sanger Sequencing and Next-Generation Sequencing Compared. News-Medical. Retrieved on January 02, 2024 from https://www.news-medical.net/life-sciences/Sanger-and-next-generation-compared.aspx.

  • MLA

    Shaffer, Catherine. "Sanger Sequencing and Next-Generation Sequencing Compared". News-Medical. 02 January 2024. <https://www.news-medical.net/life-sciences/Sanger-and-next-generation-compared.aspx>.

  • Chicago

    Shaffer, Catherine. "Sanger Sequencing and Next-Generation Sequencing Compared". News-Medical. https://www.news-medical.net/life-sciences/Sanger-and-next-generation-compared.aspx. (accessed January 02, 2024).

  • Harvard

    Shaffer, Catherine. 2019. Sanger Sequencing and Next-Generation Sequencing Compared. News-Medical, viewed 02 January 2024, https://www.news-medical.net/life-sciences/Sanger-and-next-generation-compared.aspx.

Comments

  1. Nick McCooke Nick McCooke United Kingdom says:

    You are incorrect in saying that ‘Illumina NGS’ was developed by David Klenerman at the University of Cambridge. The technology was developed by the company Solexa based on the initial ideas of David Klenerman and Shankar Balasubramanian and others. David and Shankar were founding scientists of Solexa. However the technology actually developed at U. Cambridge, Single Molecule Arrays, did not work and did not find its way into the commercial platform. Instead an array technology, bridge amplification, developed by Pascal Meyer and others in Geneva, with no connection to Cambridge University, and acquired by Solexa, was used in the commercial platform. The sequencing chemistry was invented and developed by Solexa, by Solexa scientists, and not at the University of Cambridge. Implying otherwise is a disservice to the Solexa team.
    Nick McCooke
    Former CEO, Solexa

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post